|
Shu-Lan
Yuan, Ren-Min Huang,
Xiu-Jie Wang, Yi Song, Guang-Qi Huang, Institute of Cancer
Research, West China University of Medical Sciences, Chengdu 610041,
Sichuan Province, China
Shu-Lan
Yuan, female, born
on 1964-06-25 in Jining, Shandong Province and graduated from
Shangdong Medical University in 1986, now lecturer, engaged in
research in cell and molecular biology of cancer, including
differentiation inducing therapy of tumors, having 12 papers
published.
Subject supported by the Science Fund of Chinese Ministry of Public
Health, No.1994-1-240 and China Medical Board of New York, No.9408.
Correspondence to: Shu-Lan
Yuan, Institute of
Cancer Research, West China University of Medical Sciences, Chengdu
610041, Sichuan Province, China
Telephone:
+86-28-5501282,Fax.
+86-28-5583252
Received: 1998-03-08
Subject
headings: tanshinone; liver neoplasms;
carcinoma, hepatocellular; tumor cell, cultured; cell line;
immunohistochemistry; proliferation cell nuclear antigen; flow
cytometry
Yuan SL, Huang RM, Wang XJ, Song Y, Huang GQ.Reversing effect of
Tanshinone on malignant phenotypes of human hepatocarcinoma cell
line.World J Gastroenterol, 1998;4(4):317-319
Abstract
AIM: To study the reversing effect of Chinese drug tanshinone
on malignant phenotype of cancer cells.
METHODS: Human hepatocarcinoma cell line (SMMC-7721) was
treated in vitro with 0.5mg/L tanshinone for 4 days, and variation
in cell differentiation wasdetected.RESULTS The morphology of cancer
cells was tended toward well differentiation and cell growth was
markedly inhibited. BrdU uptake assay and immunohistochemical stain
of PCNA showed that the BrdU labeling rate and PCNA positive rate
were lower than the controls, but no difference was found
statistically as compared with all transretinoic acid. Flow
cytometric assay demonstrated that S phase cells decreased and G0/G1
phase cells increased. Expression of c-myc oncogene protein
decreased but the c-fos oncogene protein markedly increased.
CONCLUSION: Tanshinone could reverse the inducing
differentiation in human hepatocarcinoma cells (SMMC-7721). It may
become a new prospective inducer of cell differentiation to treat
cancers.
INTRODUCTION
Study on reversion of cancer cells is an important field of tumor
molecular biology at present. The application of all transretinoic
acids to treating leukemia is a successful example of
differentiation inducing therapy. But attention was also been paid
to screening highly effective and low toxicant inducer of
differentiation to treat the solid tumors. Tanshinone is an alcohol
extract from the root of the traditional Chinese herbal medicine
-Salvia Miltiorrhiza Bunge. Previous studies in vitro have shown
that tanshinone possessed cytotoxic effect on cancer cells and
induced differentiation of cervical carcinoma cells[1,2].
Zhang ZW, et al reported that all transretinoic acid can
reverse malignant phenotypes of human hepatocarcinoma cells, and
promote carcinoma cells to differentiate toward normal cells[3].
We used transretinoic acids as positive control to study the
reversing effect of tanshinone on malignant phenotypes of human
hepatocarcinoma cells in cellular morphology, cellular properties of
growth and proliferation, cell cycle and expression of oncogene.
MATERIALS AND METHODS
Cell and culture
Human hepatocarcinoma cell line (SMMC-7721) was derived from
Shanghai Institute of Cancer Research[4].
Cells were cultured in RPMR1640 medium that contained 15%
inactivated bovine serum and 100mg/L ampicillin, 100mg/L
streptomycin at 37℃
in a 5% CO2 incubator.
Drugs and treatment
Tanshinone ⅡA
(Tan) was provided by the Chinese Institute for Drug and Biological
Assay (pure product). It was dissolved in DMSO (final concentration
is 0.22% V/V). The solution was filtered through a 0.22μm
microporefilter, then stored at 4℃
for use. SMMC-7721 cells were seeded, and treated with 0.5mg/L Tan
or 0.5mg/L ATRA. The control cells were added equal amount of DMSO
for negative control experiment. The cells were treated with drugs
or DMSO for 4 days continuouslly. The usage of all transretinoic
acid (ATRA, Sigma′s
product) was equal to tanshione.
Reagents
5-Bro-mo-2′-deoxyuridine
labeling and detection kit Ⅱ
is a product of Boehringer Mannheim Company, Germany.
Anti-proliferation cell nuclear antigen (PCNA) monoclonal antibody
PC10, c-myc and c-fos monoclonal antibody were purchased from
Denmark Dake Company and S-P kit from American Maxim Company.
Cellular morphological observation
The treated cells were observed under inverse and light microscopy
after HE stain. On the other hand, the cells were made into ultra
slice by routine method, and observed under transmission electron
microscopy.
Cellular growth measurement
The cells treated with drugs and control cells were harvested by
trypsinization and the total number of cells was counted by trypan
blue exclusion daily for 4 days.
BrdU labeling rate measurement
BrdU labeling The cells treated with drugs for 4 days were
continuously cultured with BrdU labelling culture liquid (final
concentration of 10μmol/L) for 30min, centrifuged and washed
with PBS, added 5% albumin PBS to make the cell smears. The diluted
1∶10
BrdU monoclonal antibody (mouse IgG1) on the smears was
added with 1∶10
anti-mouse IgAP, and developing dye (NBT, X phosphate).
Result observation The distracts of more positive cells were
chosen under low power light microscopy. The positive cells of 2000
cells were counted under oil immersion lens. The labeling rate and
positive rate were calculated.
Immunohistochemical detection
LSAB method was used for immunohistochemical staining of PCNA
according to SP-kit instruction. PC10 was diluted 1∶200
. Human tonsil tissues served as positive control and PBS
substituted PC10 for negative control. Observation of result is
similar to above.
Flow cytometry measurement
The sample preparation and measurement followed the method described
in reference[5].
The cells were harvested, counted and fixed. The cell concentration
was adjusted to 105/ml. According to the routine method,
using FACS-420 FCM, cell frequency distribution of each phase in
cell cycle was measured, and by combined with immunohistochemical
method, cell c-myc, c-fos gene and their protein expression were
detected. The results were shown with scanning figure and date.
RESULTS
Effect of Tan and ATRA on morphology of SMMC-7721 cells
Light and electron microscopy observation. In control group, the
cells arranged in aggregation, the cellular shape was polygon or
spindle, with different volumes, more tumor giant cells, large
karyon and more nucleus. The karyon/cytoplasm ratio rose, with few
organelle. In Tan or ATRA group, the cellular arrangement was
scattered, the cells became thin and long, the cellular volume
became accordant, with less tumor giant cells (Figure 1) . The
karyon became small and the nucleus became scarce. The karyon/cytoplasm
ratio fell,the well differentiated organelle such as microfilament
and Golgi complex occurred. Morphology of the cells tended towards
well differentiation as compared with the control cells (Figure 2) .
Figure 1
Tan group, morphology of SMMC-7721 cells under light microscopy. HE×100
Figure
2 Tan group, morphology of
SMMC-7721 cells under transmission electron microscopy. ×12000
Effect of Tan and ATRA on growth curve of SMMC-7721 cells
Cellular growth was measured by growth curve. The cells treated with
Tan and ATRA were markedly inhibited in logarithmic growth phase
(2-4 days after treatmentwith drugs). On day 4 after treatment with
drugs, the inhibition rates of growth were 58.1% and 52.2%. No cells
died by trypan blue exclusion.
Effect of Tan and ATRA on proliferation of SMMC-7721 cells
The BrdU labeling rate and PCNA positive rate of the Tan and ATRA
group were lower than those of control group (Table 1) , and there
was significant difference statistically (P<0.01).
But, there was no significant difference between PCNA positive rate
of Tan group and ATRA group (P>0.05).
Table 1 Effect of Tan on BrdU labeling rate and PCNA positive
rate of SMMC-7721 cells
|
Groups
|
BrdU
labeling rate (%)
|
P
|
PCNA
positive rate (%)
|
P
|
|
Control
|
28.0
|
|
74.3
|
|
|
Tan
|
8.9
|
<0.01
|
57.0
|
<0.01
|
|
ATRA
|
13.6
|
<0.01
<0.01
|
47.6
|
<0.01
>0.05
|
*Tan
compared with ATRA group by χ2 test
Effect of Tan and ATRA on cell cycle and gene expression of
SMMC-7721 cells
The results are shown in Table 2. Tan or ATRA increased the number
of cells in G0/G1 phase, but decreased the
number of cells in S phase. Tan markedly inhibited the expression of
cellular c-myc oncogene protein, but enhanced the expression of
cellular c-fos oncogene protein, while ATRA inhibited the c-myc gene
expression, but did not enhance the c-fox gene expression.
Table 2 Effect of Tan on cell cycle and gene expression of
SMMC-7721 cells
|
Groups
|
Distribution
of cell cycle (%)
|
Labeling
rate of gene expression (%)
|
|
G0/G1
|
S
|
G2+M
|
c-myc
|
c-fos
|
|
Control
|
47.7
|
16.2
|
36.1
|
23.8
|
25.9
|
|
Tan
|
57.6b
|
8.9b
|
33.5b
|
14.6b
|
41.7b
|
|
ATRA
|
59.5b
|
8.2b
|
32.3b
|
13.4b
|
28.5a
|
aP<0.05,
vs control group; bP<0.01,
vs control group
DISCUSSION
Human hepatocarcinoma cells were treated with non-cytotoxic dose of
tanshinone. After treatment, cellular morphology and structure
tended toward well-differentiation, and cellular growth and
proliferation were markedly inhibited. Trypan blue exclusion
demonstrated that the inhibiting effects of Tan and ATRA on the
cells were not caused by cytotoxicity, but by the effect of inducing
differentiation.
BrdU
labeling rate and PCNA positive rate are reliable indexes for
cellular proliferative ability. BrdU uptake test has many advantages
compared with 3H-thymidine uptake test. BrdU was a kind
of analogue of thymidine. It can incorporate the multiplicating
cells, and label the cells of S phase[6,7].
BrdU monoclonal-antibody-ligase was used as an indicator. This
method can measure the cells including BrdU, get the number of
multiplicating cells of S phase, and show the cellular DNA synthesis
ability. PCNA was an auxiliary protein of DNA polymeraseδ,
directly participate in DNA duplication in the course of cellular
multiplication. Its expression or content represents the
multiplication activity of cells. Measured positive cells are the
cells of late G1 phase or early S phase[8].
We found that BrdU labeling rate and PCNA positive rate of SMMC-7721
treated with Tan or ATRA markedly decreased. This showed that the
cellular number of S phase decreased. This result is consistent with
analysis of FCM (the cells were prevented in the G0/G1
phase of cell cycle). Previous studies have showed that the
expression of c-myc or c-fos oncogene was closely related to
cellular multiplication and differentiation. The amplification and
over expression of c-myc gene were associated with malignancy and
tumorigenicity of cells, but its low-expression was related to
cellular morphologic changes and differentiation[9].
The result of FCM showed that via the inhibition or enhancement of
expression of cellular gene, Tan and ATRA inhibited the ability of
DNA polymeraseδ and PCNA protein expression, inhibited the
cells to enter S phase and DNA synthesis, thus inhibiting the
cellular growth, multiplication, and promoted cellular
differentiation.
Tanshinone,
acting as an effective component of a traditional Chinese medicine
to induce cellular differentiation, has many advantages. It has low
toxicity and side effects, can induce tumor cells to differentiate,
at the same time, exerting other pharmacological effect. So
tanshinone is considered to be a new prospective, high effective and
low toxicant inducer of differentiation for clinical application.
REFERENCES
1 Wu WK, Chang WL, Chen CF. Cytotoxic activities
of tanshinone against human carcinoma cell lines.Am J China Med,
1991,19(3-4):207-212
2 Yuan SL, Huang GQ, Wang XJ, Zhou HY, Jiang YH.
The differentiation-inducing effect of tanshinone and retinoic acid
on
human cervical carcinoma cell line
in vitro. Chin J Oncol, 1995;17(6):424-426
3 Ai ZW, Zha XL, Tang H, Chen HL. The reversing
effect of retinoic acid on malignant phenotypes of human
hepatocarcinoma cell
line, 1991;13(1):9-12
4 Dong RC. Establishment and basic observation of
cell biological property of human hepatocarcinoma cell line
SMMC-7721.
Acad
J Mil Med Univ,1980;1(1):5-6
5 Barlogic B, Raber SJ. Flow cytometry in clinical
cancer research.Cancer Res,1983;43:3982-3985
6 Del Bino G. Morphological and clinical
significance of cell kinetics in non-Hodgkin′s
lymphomas.Basic Appl Histochem,
1986;30(1):197-199
7 Connoly KM, Bogdanffy MS. Evaluation of
proliferation cell nuclear antigen (PCNA) as endogenous marker of
cell
proliferation
in liver. A dual-stain comparison
with 5-Bromo2′-deoxy-uridinem.
J Histoche, 1993;41(1):1-4
8 Barvo R, Frank R, Blundell PA, Heather MB.
Cyclin/PCNA is the auxiliary protein of DNA polymerase δ.Nature,
1987;326(6):515-517
9 Adesson LC. Gene expression during normal and
malignant differentiation. New York: Academy Press,1985:257-262
| |